Enzyme-Linked Immunosorbent Assay Testing Market Size, Share, and Trends

Enzyme-Linked Immunosorbent Assay (ELISA) Testing Market Size, Share and Growth Analysis (By Test Type: Sandwich ELISA, Indirect ELISA, Multiple and Portable ELISA, Competitive ELISA, and Other Test Types; By Application: Immunology, Inflammation, Infectious diseases, Cancer, Protein quantification, and Others) - Global Industry Analysis, Trends, Regional Outlook, and Forecast 2023 - 2032

  • Last Updated : November 2023
  • Report Code : 1260
  • Category : Healthcare

The global enzyme-linked immunosorbent assay (ELISA) testing market size reached USD 2 billion in 2020 and is projected to hit around USD 3.43 billion by 2032, registering a CAGR of 5.60% from 2023 to 2032.

Enzyme Linked Immunosorbent Assay Testing Market Size 20123 To 2032

Access our Healthcare Data Intelligence Tool with 10000+ Database, Visit: Towards Healthcare

Key Takeaways

  • North America led the global market with the highest market share in 2022.
  • By Test Type, the sandwich ELISA segment has held the largest revenue share in 2022.
  • By Application, the infectious diseases segment has held the highest market share in 2022.

Enzyme-Linked Immunosorbent Assay (ELISA) Testing Market Size in the U.S. 2023 To 2032

The U.S. enzyme-linked immunosorbent assay (ELISA) testing market size was valued at USD 0.46 billion in 2022 and is expected to grow around USD 0.78 billion by 2030, at a CAGR of 6.4% between 2023 and 2032.

U.S.Enzyme-Linked Immunosorbent Assay (ELISA) Testing Market Size 2023 To 2032

North America is Estimated to be the Largest Market for Enzyme-Linked Immunosorbent Assay (ELISA) Testing

The research study covers key prospects and trends of enzyme-linked immunosorbent assay (ELISA) testing products throughout different regions including Europe, North America, Asia-Pacific, Middle East and Africa, and Latin America. Regionally, enzyme-linked immunosorbent assay (ELISA) testing market is dominated by North America due to large investment in research and development and existence of capable scientists. Europe accounted for the second highest share majorly due to high geriatric population. On the other hand, Asia-Pacific is anticipated to witness the rapid growth rate, on account of increasing investment by major manufacturers, high incidence of infectious disorders, and growing per-capita healthcare expenditure.

An enzyme-linked immunosorbent assay (ELISA), is a procedure that perceives and quantifies antibodies within the blood. ELISA is employed to regulate if an individual has antibodies connected to definite infectious conditions. The advent of cost-effective technologies and automation in laboratories for ELISA assay is anticipated to be the key driver for the worldwide enzyme-linked immunosorbent assay (ELISA) testing market. Furthermore, continuous advances in monoclonal antibodies (mABs) and biomarkers coupled with continuous growth in the drug discovery domain are anticipated to trigger the progress of worldwide ELISA testing industry in the near future. On the contrary, the threat of alternate testing methods using technologies such as multiplex proteomic array platforms may present a challenge to ELISA testing market. However, growing need for accurate and early ailment diagnosis owing to snowballing burden of chronic illnesses across the world along with growing geriatric populace is expected to act as prospects for ELISA testing market in close future.

ELISA testing is an important tool in various applications such as protein quantification, determination of serum antibody concentrations in a virus test, food allergen detection, presence of antigen or antibody in a sample and many more. ELISA technology offers high specificity and sensitivity for analyze detection and quantification and thus is widely used in research applications such as protein quantification during upstream and downstream processing of monoclonal antibodies (mABs), biosimilars development and other protein therapeutics development as well as biomarker selection. Worldwide, the burden of infectious diseases, cancer, HIV infection and other diseases is increasing at a rapid pace.  Increasing number of cases of infectious diseases, cancer and other diseases and increasing health awareness has led to increasing demand for accurate and early disease diagnosis tools. Continuous development of innovative and novel product for early and accurate disease diagnosis is projected to open new growth opportunities for major market players in the enzyme-linked immunosorbent assay (ELISA) testing.

Enzyme-Linked Immunosorbent Assay (ELISA) Testing Market Scope

Report Highlights Details
Growth Rate from 2023 to 2032 CAGR of 5.,60%
Market Size in 2023 USD 2.10 Billion
Market Size by 2032 USD 3.43 Billion
Base Year 2022
Forecast Period 2023 to 2032
Segments Covered Test, Application, Region
Companies Mentioned Thermo Fisher Scientific, Inc., ALPCO, Bio-Rad Laboratories, Inc., BD, BioMérieux SA, Ortho Clinical Diagnostics, R&D Systems, Inc., ZEUS Scientific, Inc.

 

Crucial factors accountable for market growth are:

  • Growing incidence of infectious disorders such as hepatitis, dengue, and AIDS
  • Increasing prevalence of neurological disorders
  • Growing geriatric population
  • High research and development expenditure of major players
  • Growing per capita healthcare spending
  • Growing incidence of non-communicable diseases
  • Emergence of cost-effective technologies

COVID-19 Impact:

The services related to prevention and treatment of non-communicable ailments has been significantly disrupted due to the COVID-19 pandemic, as per a survey published by the World Health Organization (WHO). The main result of the survey is that the healthcare facilities have been partly or entirely disrupted in many regions. Around 53% of the nations surveyed have witnessed partial or total disruption in hypertension treatment, 49% in diabetes treatment and other complications related to diabetes, 42% in treatment of cancer, and 31% in cardiovascular related emergencies. This condition is of significant worry because individuals living with non-communicable ailments are at greater risk of severe COVID-19 related sickness and mortality. Many individuals who need diagnosis for ailments like cardiovascular disease, cancer, tumor, and diabetes have faced difficulties in receiving the services and tests since the COVID-19 pandemic began.

Future of Enzyme-Linked Immunosorbent Assay (ELISA) Testing

The companies operating in the enzyme-linked immunosorbent assay (ELISA) testing market are focusing on developing software’s to regulate the results obtained through ELISA testing. These software’s help in reducing the variability of the ELISA tests.

Sandwich ELISA Test Type Reported Foremost Market Stake in 2022

Sandwich ELISA segment displayed the major share in the worldwide enzyme-linked immunosorbent assay (ELISA) testing market, by test type, in 2022. The improvements carried out in the technology in order to make the test type more efficient is the major reason for high market share of sandwich ELISA. The factors such as multiple benefits over other test types are expected to retain the dominance of continuous flow technology in the near future.

The multiple and portable ELISA is projected grow at the highest CAGR through the forecast time-frame mainly due to technological advancements.

Infectious Diseases Applications of Enzyme-Linked Immunosorbent Assay (ELISA) Testing Dominated the Market Revenue

High incidence of infectious disorders such as Lyme disease, tuberculosis, meningococcal ailments, and salmonella infections are expected to boost the growth of enzyme-linked immunosorbent assay (ELISA) testing market. Cancer applications segment is expected to grow at the highest CAGR over the forecast time-duration.

Enzyme-Linked Immunosorbent Assay (ELISA) Testing Market Players

The companies focusing on research and development are expected to lead the global enzyme-linked immunosorbent assay (ELISA) testing market. Leading competitors contending in global enzyme-linked immunosorbent assay (ELISA) testing market are as follows:

  • Thermo Fisher Scientific, Inc.
  • American Laboratory Products Company (ALPCO)
  • Bio-Rad Laboratories, Inc.
  • BD
  • BioMérieux SA
  • Ortho Clinical Diagnostics
  • R&D Systems, Inc.
  • ZEUS Scientific, Inc.

In order to well recognize the present status of enzyme-linked immunosorbent assay (ELISA), and policies implemented by the foremost nations, Precedence Research projected the future progress of the enzyme-linked immunosorbent assay (ELISA) testing market. This research report bids quantitative and qualitative insights on enzyme-linked immunosorbent assay (ELISA) testing market and valuation of market size and progress trend for probable market segments.

Key Market Developments:

On November, 2019, ALPCO announced the official launch of its STELLUX Chemi Glucagon ELISA. The new chemiluminescence ELISA features increased analytical specificity and a broad range to accurately quantify glucagon levels between 0.86 and 143.7 pmol/L (3-500 pg/mL) in human and rodent samples.

Major Market Segments Covered:

By Test Type

  • Sandwich ELISA
  • Indirect ELISA
  • Multiple and Portable ELISA
  • Competitive ELISA
  • Others

By Application

  • Immunology
  • Inflammation
  • Infectious diseases
  • Cancer
  • Protein quantification
  • Other Applications

By Geography

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa (MEA)

Frequently Asked Questions

The global enzyme-linked immunosorbent assay (ELISA) testing market size was valued at USD 2 billion in 2022 and is predicted to reach USD 3.43 billion by the end of 2032, representing impressive CAGR of 5.60% during the forecast period 2023 to 2032.

The global enzyme-linked immunosorbent assay (ELISA) testing market is representing impressive CAGR of 5.60% during the forecast period 2023 to 2032.

Factors such as growingincidence of infectious disorders such as hepatitis, dengue, and AIDS, increasing prevalence of neurological disorders, growing geriatric population, high research and development expenditure of major players, growing per capita healthcare spending, growing incidence of non-communicable diseases, and emergence of cost-effective technologies are driving the growth of enzyme-linked immunosorbent assay (ELISA) testingmarket.Increasing focus on laboratory automation and growing R&D activities in monoclonal antibodies (mABs) and biomarkers are further propelling the enzyme-linked immunosorbent assay (ELISA) testingmarket expansion across the globe. The most important advantage of using ELISA is its specificity and sensitivity with antibodies that are customized for a spec

In 2020, North America dominated the global market with a market share of more than 42%.

The Asia Pacific region is projected to lead with highest CAGR of about 7.8% in the estimate duration majorly because of high frequency of infectious ailments.African, Latin American, and Middle Eastern region will display perceptible progress.

The major companies operating in the worldwide enzyme-linked immunosorbent assay (ELISA) test market are ZEUS Scientific, Inc., Thermo Fisher Scientific, Inc., R&D Systems, Inc., American Laboratory Products Company (ALPCO), Bio-Rad Laboratories, Inc., BD, BioMérieux SA, and Ortho Clinical Diagnostics, among others.

Enzyme-Linked Immunosorbent Assay (ELISA) also named enzyme immunoassay (EIA) is a plate-based assay procedure for discovery and evaluation of substances such as antibodies, hormones, proteins, etc. The ELISA has been employed widely as a significant diagnostic instrument in plant pathology, medicine, as well as a quality-control audit in biotech and pharmaceutical industries. ELISA assay procedure is based on precise antigen antibody attachment. The antigen, to be evaluated, is immobilized on a solid surface and then is complexed with antibody which is linked to an enzyme. Recognition is accomplished by measuring the coupled enzyme activity via incubation with a substrate to manufacture a product that can be calculated. ELISA has usage in various domains such as allergen recognition in th

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. Market Dynamics Analysis and Trends

5.1. Market Dynamics

5.1.1. Market Drivers

5.1.2. Market Restraints

5.1.3. Market Opportunities

5.2. Porter’s Five Forces Analysis

5.2.1. Bargaining power of suppliers

5.2.2. Bargaining power of buyers

5.2.3. Threat of substitute

5.2.4. Threat of new entrants

5.2.5. Degree of competition

Chapter 6. Competitive Landscape

6.1.1. Company Market Share/Positioning Analysis

6.1.2. Key Strategies Adopted by Players

6.1.3. Vendor Landscape

6.1.3.1. List of Suppliers

6.1.3.2. List of Buyers

Chapter 7. Global Enzyme-Linked Immunosorbent Assay (ELISA) Testing Market, By Test Type

7.1. Enzyme-Linked Immunosorbent Assay (ELISA) Testing Market, by Test Type, 2023-2032

7.1.1. Sandwich ELISA

7.1.1.1. Market Revenue and Forecast (2020-2032)

7.1.2. Indirect ELISA

7.1.2.1. Market Revenue and Forecast (2020-2032)

7.1.3. Multiple and Portable ELISA

7.1.3.1. Market Revenue and Forecast (2020-2032)

7.1.4. Competitive ELISA

7.1.4.1. Market Revenue and Forecast (2020-2032)

7.1.5. Others

7.1.5.1. Market Revenue and Forecast (2020-2032)

Chapter 8. Global Enzyme-Linked Immunosorbent Assay (ELISA) Testing Market, By Application

8.1. Enzyme-Linked Immunosorbent Assay (ELISA) Testing Market, by Application, 2023-2032

8.1.1. Immunology

8.1.1.1. Market Revenue and Forecast (2020-2032)

8.1.2. Inflammation

8.1.2.1. Market Revenue and Forecast (2020-2032)

8.1.3. Infectious diseases

8.1.3.1. Market Revenue and Forecast (2020-2032)

8.1.4. Cancer

8.1.4.1. Market Revenue and Forecast (2020-2032)

8.1.5. Protein quantification

8.1.5.1. Market Revenue and Forecast (2020-2032)

8.1.6. Other Applications

8.1.6.1. Market Revenue and Forecast (2020-2032)

Chapter 9. Global Enzyme-Linked Immunosorbent Assay (ELISA) Testing Market, Regional Estimates and Trend Forecast

9.1. North America

9.1.1. Market Revenue and Forecast, by Test (2020-2032)

9.1.2. Market Revenue and Forecast, by Application (2020-2032)

9.1.3. U.S.

9.1.3.1. Market Revenue and Forecast, by Test (2020-2032)

9.1.3.2. Market Revenue and Forecast, by Application (2020-2032)

9.1.4. Rest of North America

9.1.4.1. Market Revenue and Forecast, by Test (2020-2032)

9.1.4.2. Market Revenue and Forecast, by Application (2020-2032)

9.2. Europe

9.2.1. Market Revenue and Forecast, by Test (2020-2032)

9.2.2. Market Revenue and Forecast, by Application (2020-2032)

9.2.3. UK

9.2.3.1. Market Revenue and Forecast, by Test (2020-2032)

9.2.3.2. Market Revenue and Forecast, by Application (2020-2032)

9.2.4. Germany

9.2.4.1. Market Revenue and Forecast, by Test (2020-2032)

9.2.4.2. Market Revenue and Forecast, by Application (2020-2032)

9.2.5. France

9.2.5.1. Market Revenue and Forecast, by Test (2020-2032)

9.2.5.2. Market Revenue and Forecast, by Application (2020-2032)

9.2.6. Rest of Europe

9.2.6.1. Market Revenue and Forecast, by Test (2020-2032)

9.2.6.2. Market Revenue and Forecast, by Application (2020-2032)

9.3. APAC

9.3.1. Market Revenue and Forecast, by Test (2020-2032)

9.3.2. Market Revenue and Forecast, by Application (2020-2032)

9.3.3. India

9.3.3.1. Market Revenue and Forecast, by Test (2020-2032)

9.3.3.2. Market Revenue and Forecast, by Application (2020-2032)

9.3.4. China

9.3.4.1. Market Revenue and Forecast, by Test (2020-2032)

9.3.4.2. Market Revenue and Forecast, by Application (2020-2032)

9.3.5. Japan

9.3.5.1. Market Revenue and Forecast, by Test (2020-2032)

9.3.5.2. Market Revenue and Forecast, by Application (2020-2032)

9.3.6. Rest of APAC

9.3.6.1. Market Revenue and Forecast, by Test (2020-2032)

9.3.6.2. Market Revenue and Forecast, by Application (2020-2032)

9.4. MEA

9.4.1. Market Revenue and Forecast, by Test (2020-2032)

9.4.2. Market Revenue and Forecast, by Application (2020-2032)

9.4.3. GCC

9.4.3.1. Market Revenue and Forecast, by Test (2020-2032)

9.4.3.2. Market Revenue and Forecast, by Application (2020-2032)

9.4.4. North Africa

9.4.4.1. Market Revenue and Forecast, by Test (2020-2032)

9.4.4.2. Market Revenue and Forecast, by Application (2020-2032)

9.4.5. South Africa

9.4.5.1. Market Revenue and Forecast, by Test (2020-2032)

9.4.5.2. Market Revenue and Forecast, by Application (2020-2032)

9.4.6. Rest of MEA

9.4.6.1. Market Revenue and Forecast, by Test (2020-2032)

9.4.6.2. Market Revenue and Forecast, by Application (2020-2032)

9.5. Latin America

9.5.1. Market Revenue and Forecast, by Test (2020-2032)

9.5.2. Market Revenue and Forecast, by Application (2020-2032)

9.5.3. Brazil

9.5.3.1. Market Revenue and Forecast, by Test (2020-2032)

9.5.3.2. Market Revenue and Forecast, by Application (2020-2032)

9.5.4. Rest of LATAM

9.5.4.1. Market Revenue and Forecast, by Test (2020-2032)

9.5.4.2. Market Revenue and Forecast, by Application (2020-2032)

Chapter 10. Company Profiles

10.1. Thermo Fisher Scientific, Inc.

10.1.1. Company Overview

10.1.2. Product Offerings

10.1.3. Financial Performance

10.1.4. Recent Initiatives

10.2. American Laboratory Products Company (ALPCO)

10.2.1. Company Overview

10.2.2. Product Offerings

10.2.3. Financial Performance

10.2.4. Recent Initiatives

10.3. Bio-Rad Laboratories, Inc.

10.3.1. Company Overview

10.3.2. Product Offerings

10.3.3. Financial Performance

10.3.4. Recent Initiatives

10.4. BD

10.4.1. Company Overview

10.4.2. Product Offerings

10.4.3. Financial Performance

10.4.4. Recent Initiatives

10.5. BioMérieux SA

10.5.1. Company Overview

10.5.2. Product Offerings

10.5.3. Financial Performance

10.5.4. Recent Initiatives

10.6. Ortho Clinical Diagnostics

10.6.1. Company Overview

10.6.2. Product Offerings

10.6.3. Financial Performance

10.6.4. Recent Initiatives

10.7. R&D Systems, Inc.

10.7.1. Company Overview

10.7.2. Product Offerings

10.7.3. Financial Performance

10.7.4. Recent Initiatives

10.8. ZEUS Scientific, Inc.

10.8.1. Company Overview

10.8.2. Product Offerings

10.8.3. Financial Performance

10.8.4. Recent Initiatives

Chapter 11. Research Methodology

11.1. Primary Research

11.2. Secondary Research

11.3. Assumptions

Chapter 12. Appendix

12.1. About Us

12.2. Glossary of Terms

Proceed To Buy

USD 4900
USD 3800
USD 2100
USD 2100
USD 7500

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client